Mycobacterium tuberculosis Complex, Pyrazinamide Resistance by pncA DNA Sequencing, Varies
Use
The test is used for the detection of genotypic resistance to pyrazinamide in Mycobacterium tuberculosis complex isolates. The sequencing provides a more rapid susceptibility result compared to phenotypic broth methods, usually within 1 day after isolate growth. It identifies mutations in the pncA gene that correlate with resistance, offering critical information for treatment planning, especially in managing drug-resistant tuberculosis.
Special Instructions
Specimen source and suspected organism identification are required unless concurrent identification test is ordered. Organism must be in pure culture and actively growing before shipping. Use provided Infectious Container (T146) and follow Infectious Specimen Shipping Guidelines.
Limitations
The test detects mutations in the pncA gene linked to resistance, but will not identify other resistance mechanisms like changes in PZA uptake or efflux. Interpretation should consider clinical presentation, and further testing may be necessary for new or ambiguous polymorphisms. Although most PZA-resistant strains have pncA mutations, some strains may not be detected by this method.
New York Approved
Methodology
Sanger
Biomarkers
LOINC Codes
- 46245-7
- 46245-7
Result Turnaround Time
7-21 days
Related Documents
For more information, please review the documents below
Specimen
Other
Volume
Isolate
Minimum Volume
Not provided
Container
Middlebrook 7H10 agar slant
Collection Instructions
Organism must be in pure culture, actively growing.
Causes for Rejection
Agar plate